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Abstract 
Mitochondria are not only the “power-house” of the cell, but are also involved in a multitude 
of processes that include calcium storage, cell-cycle and cell-death. Traditional means to 
investigate mitochondrial importance in a given cellular process have centred upon depletion 
of mitochondrial DNA (mtDNA) through chemical or genetic means. While these methods 
severely disrupt mitochondrial electron transport chain, mtDNA-depleted cells still maintain 
mitochondria and many mitochondrial functions. Here, we describe a straightforward 
protocol to generate mammalian cell populations with low to non-detectable levels of 
mitochondria. Ectopic expression of the ubiquitin E3 ligase Parkin, combined with short-term 
mitochondrial uncoupler treatment, engages widespread mitophagy, and effectively 
eliminates mitochondria. In this protocol, we explain how to generate mitochondria-depleted 
cells and a variety of methods to confirm mitochondrial clearance. Furthermore, we describe 
culture conditions to maintain mitochondrial-depleted cells with minimal loss of viability for 
longitudinal studies. This method should prove useful to investigate the importance of 
mitochondria in a variety of biological processes. 
Introduction 
Mitochondria have traditionally been viewed as the powerhouse of the cell due to 
their central role in metabolism and energy production. More recently, mitochondria have 
been implicated in a wide-variety of other cellular roles including calcium storage, migration, 
cell death, senescence and inflammation1. Equally, impairment of mitochondrial homeostasis 
has been heavily linked to a wide range of diseases2,3; for this reason understanding the 
mechanisms that regulate mitochondrial health is of fundamental importance. To this end, 
eukaryotic cells are equipped with a range of mitochondrial quality control (QC) mechanisms 
4,5. 
  
Mitochondria-specific autophagy, hereafter termed mitophagy, is a key mitochondrial 
QC mechanism that helps maintain mitochondrial fitness by efficiently removing 
dysfunctional organelles. While several different mechanisms regulating mitophagy have 
been described in mammalian cells, the best understood is PINK1/PARKIN-mediated 
mitophagy6. In this process, mitophagy occurs primarily following a complex interplay 
between the Ser/Thr kinase PINK1 and the E3 ubiquitin ligase PARKIN4. In healthy 
mitochondria PINK1 is subject to constant turnover; cleavage of its mitochondrial targeting 
sequence by the mitochondria intermembrane space protease PARL reveals a destabilizing 
N-terminal residue that targets PINK for proteasomal degradation7,8. Disruption of 
mitochondrial function causes an accumulation of PINK1 on the mitochondrial outer 
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membrane where it phosphorylates ubiquitin and Parkin leading to activation of the PARKIN 
E3 ubiquitin ligase at the mitochondria9-11. Parkin recruitment to mitochondria requires 
mitofusin 2 (MFN2) in some settings 12,13 but is dispensible in others 14. In a feed-forward 
mechanism, Parkin ubiquitinates mitochondrial substrates that, in turn, leads to more PINK1 
substrate phosphorylation and Parkin activity. Ubiquitinated mitochondria are targeted for 
autophagy following recognition by specific ubiquitin binding adaptor proteins9. Importantly, 
experimentally induced PINK1/Parkin-mediated mitophagy can reduce mitochondrial levels 
to below the level of detection, thereby opening its use as an experimental tool to study 
mitochondrial function15,16. 
 
Development of an assay that allows the generation of mitochondria-depleted cells 
A well-established approach to study mitochondrial function in various processes centres 
upon depleting mitochondrial DNA (mtDNA) to generate so-called ρ0 cells 17. Typically this is 
achieved by long-term culture in the presence of ethidium bromide (EtBr) that inhibits 
replication of mitochondrial but not nuclear DNA. Nevertheless, this method has various 
drawbacks including the extended time required to generate ρ0 cells (typically weeks) and 
potential unwanted mutagenic effects on genomic DNA caused by EtBr treatment. 
Alternative methods to deplete mtDNA and generate ρ0 cells include mitochondrial targeting 
of the restriction endonuclease EcoRI 18 or expression of a dominant negative form of Polγ, a 
gene that codes for the catalytic subunit of the mitochondrial DNA polymerase 19. However, 
these solutions do not circumvent a major drawback, which is that ρ0 cells still contain 
functional mitochondria. For example, mitochondrial apoptosis proceeds efficiently in ρ0 cells 
20. This prompted us to develop a method to remove mitochondria, allowing the study of 
cellular functions in the absence of all aspects of mitochondrial biology.    
Herein, we describe a facile protocol that exploits PINK1/Parkin-mediated mitophagy as a 
tool to investigate mitochondrial function. In short, the method entails overexpression of 
Parkin and short-term mitochondrial depolarization to stimulate widespread mitophagy. This 
generates mammalian cells with low to non-detectable mitochondrial content allowing 
comparison of matched cells proficient or deficient in mitochondria (Figure 1). Demonstrating 
the protocol’s effectiveness mitochondria-depleted cells show no detectable mitochondrial 
respiration, proteins or mtDNA, and strikingly no mitochondrial organelles were observed by 
3D electron microscopy 15,16. Following mitochondrial depletion, cells fail to repopulate their 
mitochondrial population over extended periods of time (16 days post removal of CCCP), 
demonstrating effective depletion. Furthermore, we have developed culture conditions to 
keep mitochondrial-depleted cells in culture with minimal loss of viability for long periods of 
time ranging from 5 days to 1 month  (depending on the cell type) allowing extensive 
longitudinal studies.  
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Applications of the widespread-mitophagy protocol 
1. Investigating the role of mitochondria in cell death  
Mitochondria are often essential in the execution of programmed cell death (or apoptosis). 
The intrinsic pathway of apoptosis is also called  “mitochondrial apoptosis” since the 
permeabilisation of mitochondria is required for caspase activation and cell death 21. A 
recently described non-apoptotic type of cell death is necroptosis (programmed necrosis) 
that requires the executioner protein mixed lineage kinase domain-like (MLKL) 22. 
Mitochondria, through the generation of ROS, were considered essential for the execution of 
necroptosis 23-25. To directly test this, we used Parkin-mediated mitophagy to efficiently 
remove mitochondria and assess its effect on necroptosis and apoptosis. As expected, 
mitochondrial-depleted cells were resistant to mitochondrial apoptosis 15.  However, while 
Parkin-mediated mitophagy completely prevented ROS production, it did not impact on 
necroptosis execution. This provided the first evidence that mitochondria are dispensable for 
the execution of necroptosis 15. 
2. Investigating the role of mitochondria in cellular senescence  
Senescence is a cellular response to a variety of stresses, including oncogene activation, 
DNA damage and telomere dysfunction, that permanently arrests the cell. Senescence has 
been involved in several processes including development, cancer and tissue remodelling. 
Furthermore, increasing evidence suggests that senescence are major contributors to age-
related tissue dysfunction and pathologies, mostly by the development of a pro-oxidant and 
pro-inflammatory phenotype 26. Mitochondrial dysfunction is a feature of senescence 27 and 
has been shown to induce and stabilise the senescence arrest mostly via generation of 
ROS-driven cellular damage 28. Despite the fact that multiple biochemical reactions occur 
within mitochondria, it is still relatively unknown what other factors apart from ROS impact on 
the senescent phenotype. By inducing Parkin-mediated widespread mitophagy our group 
has demonstrated that these organelles are required for the development of both the pro-
oxidant  and pro-inflammatory senescence-associated phenotypes 16. This approach 
demonstrated the requirement of mitochondria for the development of several features of the 
senescent phenotype which are considered drivers of the ageing process, suggesting these 
organelles as putative therapeutic targets for interventions to inhibit senescence and ageing. 
3. Mitophagy as readout of autophagic flux 
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Autophagy is a recycling process delivering various cytosolic cargoes (including whole 
organelles such as mitochondria or the peroxisomes) to lysosomes for degradation. 
Autophagy has lately received considerable attention due to its involvement in a multitude of 
human diseases, ranging from neurodegenerative disorders to cancer 29,30. It is therefore 
important to develop reliable methods for assessing the autophagic flux in vitro. This is 
especially relevant when testing new autophagy inhibitors that could be translated into 
clinical trials. The most commonly used method to characterize autophagy is the western 
blotting or immunofluorescence detection of lipidated LC3 (or LC3-II) which is indicative of 
autophagosome assembly. Nevertheless, inhibition of autophagosome breakdown or 
stimulation of autophagy can both increase LC3 II levels thereby complicating analysis. As 
such, a quantitative measure of autophagic flux is a much preferable measure. To address 
this issue, our lab has recently used the Parkin-mediated mitophagy protocol as a read-out 
of autophagic flux31. Briefly, mitophagy was used to detect differences in the autophagic flux 
between various cell lines with accurate detection and characterization of the effect of 
pharmacological or genetic inhibition/promotion of autophagy31. 
 
4. Additional Applications  
 
Generation of transmitochondrial cybrids. Using this method, mitochondria can be 
eliminated from cells followed by cell fusion with cytoplasts containing different degrees of 
mtDNA mutations. This method allows the investigation of mitochondrial diseases, without 
the need to use of ρ0 cells- which still contain dysfunctional mitochondrial organelles. 
Investigating mitochondrial biogenesis: We have found that if lower concentrations of 
CCCP are used and incomplete Parkin-mediated mitochondrial clearance occurs, 
mitochondria can repopulate. This will allow cell studies to investigate kinetics and 
determinants of mitochondrial replication. 
Drug/genetic screens aiming to identify novel pathways that are dependent/independent of 
mitochondrial function. 
 
Advantages, limitations and adaptations 
Traditional methods to perturb mitochondrial function have relied on deletion of mtDNA, 
typically through long-term ethidium bromide treatment 17. Nevertheless, while this effectively 
depletes mtDNA, mitochondria themselves and many of its associated functions remain in 
the cell. Moreover, it takes a considerable amount of time to achieve mtDNA depletion 
(weeks to months) and ethidium bromide may exert unwanted effects upon nuclear DNA. 
The protocol described below, using the Parkin-mediated mitochondrial depletion, addresses 
these issues by completely removing mitochondria in a quick (24 - 48 hours) and specific 
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manner. Furthermore, this approach enables the generation of cell populations that show 
high penetrance of mitochondrial depletion (over 95% of cells with no detectable 
mitochondria) and therefore greatly facilitates the study of mitochondria in various cellular 
processes. 
Potential limitations of this assay are that some cells do not readily survive mitochondrial 
depletion. In our own experience, all cell lines we have used show minimal cytotoxicity in 
reponse to short-term CCCP or antimycin A/oligomycin treatment. However, activation of 
Parkin-mediated mitophagy can cause extensive caspase-dependent apoptosis in some cell 
lines (HeLa for example). For unclear reasons, this cytoxicity appears cell-type dependent 
nevertheless it can be prevented by the co-application of caspase inhibitors.  Secondly, the 
use of chemicals such as CCCP to induce mitophagy can have unwanted off-target effects32. 
Additionally, effective mitochondrial depletion requires ectopic expression of Parkin which 
may exert unwanted effects on the biological process being investigated. An approach to 
circumvent this may be through the use of an inducible Parkin expression vector, such that 
Parkin expression is switched off post-mitophagy. Finally, while the transduction of 
immortalised cells is often highly efficient, generation of stable cell lines using primary cells 
can be more troublesome - below we describe a protocol for both immortalised and primary 
cell lines.  
 
Experimental design 
The protocol can be divided into three main parts: generation of a stable YFP-Parkin-
expressing cell line (Steps 1–10); induction of widespread mitophagy (Steps 11-13); and 
long-term culture of mitochondria-depleted cells. We finish with a brief summary for readouts 
of widespread mitophagy. 
 
Generation of a stable YFP-Parkin-expressing cell line. In this protocol, we describe how 
to generate a stable YFP-Parkin-expressing cell line in primary human fibroblasts. 
Nevertheless, similar procedures have been successfully tested in other human primary 
(e.g., IMR-90 primary) and immortalised cells (e.g. KP-4 and HeLa cells) and murine cells 
(e.g. SVEC and 3T3 cell). We also describe cell culture conditions were primary fibroblasts 
can be maintained viable for up to a month following mitochondrial depletion allowing for 
kinetics assays and long-term studies.  
 
In this protocol we use Phoenix Amphotropic cells to produce retroviral particles. Phoenix™ 
Amphotropic packaging cell lines are second generation retrovirus producer lines that were 
generated from human embryonic kidney (HEK) 293T cells33,34. In addition to the 
temperature sensitive T antigen co-selected with neomycin already present in HEK293T 
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cells, PhoenixTM Amphotropic cells contain two extra constructs: a construct capable of 
producing the gag-pol and a construct for the codification of the envelope protein for 
amphotropic viruses. Both the gag-pol and the envelope protein sequences were introduced 
with hygromycin and diphtheria toxin resistance as the co-selectable markers, respectively. 
The expression of each constructs is under regulation of different non-Moloney promoters to 
minimize recombination potential. The incorporation of these constructs in the Phoenix cells 
makes the transfection process relatively easy in these cells, where packaging cells 
(PhoenixTM Amphotropic cells), retroviral vectors and the transfection reagent are the only 
required transfection components (no requirement of additional packaging constructs). This 
cell line is highly transfectable with either calcium phosphate mediated transfection or lipid-
based transfection protocols, with ≥ 50% cells being transiently transfected. In this protocol 
we use and describe a lipid-based transfection protocol using LipofectamineTM.  
 
Next, we describe a protocol for transduction of YFP-Parkin retroviral particles into human 
primary fibroblasts. Human diploid fibroblasts, such as MRC5 fibroblasts, undergo a finite 
number of cell divisions or population doublings (PD) before permanently arresting in the cell 
cycle in a state termed replicative senescence 35. Therefore, following a precise protocol 
when culturing and generating stable primary human fibroblasts cell lines is essential. For 
this reason, calculating the PD of human primary fibroblasts is required to evaluate the 
numbers of cell divisions that these cells have undergone and avoid transducing cells that 
are reaching their proliferative limit. Human fibroblasts are also sensitive to cell confluency: 
under confluency (≤ 40% cell density) or over confluency (≥100 % cell density) can induce 
cellular stress and lead to premature senescence. It is thus necessary to calculate cell 
density for optimised cell fitness, transduction and posterior selection with antibiotics (e.g. 
ZeocinTM). 
 
Induction of widespread Mitophagy. In this protocol, widespread mitophagy is achieved by 
inducing overall mitochondrial depolarisation. Carbonyl cyanide 3-chlorophenylhydrazone 
(CCCP) is a protonophore (H+ ionophore) and uncoupler of oxidative phosphorylation in 
mitochondria that promotes loss ∆ψm and morphological swelling 36. Treatment of YFP-
Parkin-expressing cells with CCCP ensues mitochondrial dysfunction and translocation of 
Parkin to mitochondria, where it binds to PINK1 that has accumulated in the outer-
mitochondrial membrane. An alternative to CCCP, as it can show off-target effects on 
lysosomal function 32, is a mix of Antimycin A and Oligomycin A (in equimolar amounts) 
which are specific mitochondrial uncouplers. Typically, the widespread mitophagy protocol 
takes 48 hours. While immortalized cells require treatment with the mitochondrial membrane 
uncoupler every 12 hours, primary cells only require treatment every 24 hours for 48 hours. 
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Note, the mitochondrial uncoupler dose and treatment duration should be tested for each cell 
line in order to efficiently induce widespread mitochondrial depletion.   
 
Long-term culture of mitochondria-depleted cells  
Here we describe the culture conditions that allow long-term culturing  of cells depleted of 
mitochondria. This is mainly achieved by supplementing the growth media with uridine.  
 
Assessment of mitophagy. The effectiveness of induced mitophagy can be assessed in 
multiple ways but typically relies upon detection of loss of mitochondrial protein(s) signal or 
loss of mtDNA. Importantly, Parkin has been shown to target some mitochondrial proteins for  
proteasomal degradation independently of mitophagy 37,38. Therefore, multiple approaches 
should be used, at least in initial experiments, to verify the method is functional.  
 
Materials 
REAGENTS 
Cell culture  
Critical: The cell lines used should be regularly checked to ensure that they are authentic 
and not infected with Mycoplasma. Although mycoplasma contamination does not affect 
induction of mitophagy it can affect several cellular functions and viability. 
 
The generation of a YFP-Parkin expressing cell line involves the culturing of a packaging cell 
line for YFP-Parkin retroviral production, in this case PhoenixTM Amphotropic cells, and a cell 
line that will be subject to YFP-Parkin-retroviral transduction and become the YFP-Parkin 
expressing cell line (Table 1). 
 
 
The indicated reagents or suppliers listed below can be substituted with appropriate 
alternatives if necessary. 
 
• Dulbecco’s modified Eagle’s medium (DMEM, Cat. Number D5796, Sigma) 
• Penicillin-Streptomycin (Cat. Number P4333, Sigma)  
• Fetal bovine Serum (FBS, Cat. Number F9665, Sigma, Dorset) 
• L-Glutamine (Cat. Number G7513, Sigma, Dorset)  
• Trypsin-EDTA (TE) (Cat.Number T3924, Sigma) 
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• Opti-MEM® I Medium (Cat. Number 11058-021, Thermo Fisher Scientic) 
• MEM NEAA (Minimum Essential Medium Non-Essential Amino Acids) (Cat. Number 
11140, Life Technologies) 
• Sodium pyruvate (Cat. Number S8636, Sigma-Aldrich)  
• 2-Mercaptoethanol (Cat. Number 21985, Life Technologies) 
• Phosphate Buffer Saline (Cat. Number D1408, Sigma) 
 
YFP-Parkin vector transfection and retroviral transduction  
• YFP-Parkin-IRES-zeocin (Addgene, ID number 61728) 
Note: mCherry-Parkin-IRES-zeocin is also available (Addgene, ID number 61727) 
• LipofectamineTM 2000 (Cat. Number 11668-019, Invitrogen,) 
• Polybrene (Cat . Number sc-134220, Santa Cruz) 
Caution: Polybrene is toxic if swallowed or in contact with the skin/eyes. Avoid 
contact with skin and eyes. Avoid formation of aerosols and provide appropriate 
exhaust ventilation at places where aerosols are formed. 
Selection of efficiently transduced cells  
• ZeocinTM (Cat. Number R25001, Invitrogen) 
Caution: ZeocinTM is toxic if swallowed or in contact with the skin/eyes. ZeocinTM is 
also suspected of causing genetic defects (mutagen). Avoid direct contact, and use 
gloves while preparing and using ZeocinTM. Avoid formation of aerosols and provide 
appropriate exhaust ventilation. 
 
Induction of mitophagy 
• Carbonyl cyanide 3-chlorophenylhydrazone (CCCP, Cat number C2759, Sigma)  
Caution: CCCP is toxic if swallowed, in contact with the skin/eyes or if inhaled. Avoid 
direct contact, and use gloves while preparing and using CCCP. Avoid formation of 
dust and aerosols. Provide appropriate exhaust ventilation. 
• Antimycin A (Cat number A8674, Sigma)  
 Caution: Antimycin A is fatal if swallowed and toxic if in contact with the skin/eyes or 
if inhaled. Avoid direct contact, and use gloves while preparing and using Antimycin 
A. Avoid formation of dust and aerosols. Provide appropriate exhaust ventilation at 
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places where dust/ aerosols is formed. Antimycin A is also toxic to aquatic life and 
therefore requires disposal of contents/ container to an approved waste disposal 
plant.  
• Oligomycin A (Cat number 75351, Sigma)  
 Caution: Oligomycin A is harmful if swallowed, in contact with the skin/eyes or if 
inhaled. Avoid direct contact, and use gloves while preparing and using Oligomycin 
A. Avoid formation of dust and aerosols. Provide appropriate exhaust ventilation at 
places where dust/aerosols is formed. 
 
Assessment of widespread mitophagy 
 
Detection of mitochondrial proteins 
 
Detection of mitochondrial proteins using western blot and/or immunofluorescence staining 
can be performed using conventional protocols and reagents. In Table 2 we describe the 
antibodies used for mitochondrial proteins detection used in this protocol. 
 
Detection of mitochondrial proteins can also be achieved by live-cell imaging of YFP-Parkin 
cells expressing a mitochondrial targeted protein (for instance mito-dsRRed; Clontech, Cat. 
Number 632421). 
 
Quantification of mtDNA abundance  
Detection of mtDNA is performed by qPCR. Below we describe the mtDNA and nuclear 
(control) primers for mtDNA analysis used in this protocol (Table 3). 
 
 
EQUIPMENT 
• Centrifuge tubes, 15 ml (Cat. Number E1415-0200, Starlab) 
• Centrifuge tubes, 50 ml (Cat. Number E1450-0200, Starlab) 
• Microcentrifuge tubes, 1.5 ml (Cat. Number E1415-1510, Starlab) 
• Refrigerators, 4 and −20 °C 
• HeracellTM 150i CO incubator (ThermoScientific) 
• Microcentrifuge 5415R (Eppendorf) 
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• Corning® cell culture flasks surface area 75 cm2, canted neck (Cat. Number 
CLS430641-100EA, Sigma) 
• Corning® Costar® cell culture plates 6 well (Cat. Nu,mber CLS3506-100EA, Sigma) 
• Corning® Costar® cell culture plates 12 well (Cat. Nu,mber CLS3512-100EA, Sigma) 
• Corning Tissue Culture Treated Culture Dishes 100mm X 20mm (Cat. Nubmber 
CLS430167-500EA, Sigma) 
• Cover Glass, Ø 19mm, Thickness 0.16mm (Cat. Number 631-0156, VWR) 
• Millex-HV 0.45 μm PVDF filters (Millipore, cat. no. SLHVR25LS) 
• 35 mm glass-bottom dishes (Cat Number P35G-1.5-20-C, MatTek) 
• Nikon TE2000 microscope with Perfect Focus System (PFS). The system is 
equipped with a Sutter Lambda 10-3 controller, ASI MS2 XY stage with linear 
encoders, Photometrics CoolSnap HQ CCD camera and Metamorph 7.5 software. 
 
REAGENT SETUP 
Culture medium for human Phoenix Amphotropic cells 
Supplement DMEM medium with 10% (vol/vol) FBS, 100 units/ml penicillin, 100 μg.ml-1 
streptomycin, 2 mM glutamine, 1mM sodium pyruvate, 300 μg.ml-1 Hygromycin B and 1 
μg.ml-1 Diphtheria toxin. This medium can be stored at 4 °C for up to 1 month.  
 
Culture medium for human MRC5 fibroblasts 
Supplement DMEM medium with 10% (vol/vol) FBS, 100 units/ml penicillin, 100 μg.ml-1 
streptomycin and 2 mM glutamine. This medium can be stored at 4 °C for up to 1 month.  
 
 
Culture medium for human MRC5 fibroblasts without mitochondria 
Supplement DMEM medium with 10% (vol/vol) FBS, 100 units/ml penicillin, 100 μg.ml-1  
streptomycin, 2 mM glutamine and 50 μg.ml-1 uridine. This medium can be stored at 4 °C for 
up to 1 month.  
 
 
Mitochondrial membrane uncouplers 
• Dissolve CCCP in DMSO to a stock concentration of 125 mM. Dilute to a final 
concentration of 12.5 µM (1:10000) in complete medium, just before adding it to the 
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cells (add the same volume of DMSO to complete medium if needed a vehicle 
control). CCCP (stock solution of 125 mM) can be stored at -20 °C, protected from 
light for 6 months.  
Critical: Prepare small aliquots of CCCP stock solution (125 mM) and freeze them at 
-20oC. Avoid freeze/thawing cycles as this may reduce CCCP efficiency. 
• Dilute Antimycin A and Oligomycin A in ethanol (100%) to a stock concentration of 1 
mM and small volume aliquots (20-50 μl) are kept at -20°C. Dilute to a final 
concentration of 1 µM (1:1000) in complete medium, just before adding to the cells 
(add the same volume of ethanol to complete medium if needed a vehicle control). 
Antimycin A and Oligomycin A solutions can be stored at -20 °C for 6 months.  
 
 
 
Procedure 
Generation of YFP-Parkin-expressing cell line 
 
Steps 1 to 4 summarize the transfection of YFP-Parkin vector into PhoenixTM Amphotrophic 
cell and generation of retroviral particles. Timing: 4-5 days 
Critical step: Transfection protocols are performed following Biosafety level 2 (BL-2) 
procedures. 
 
1. Day 1 
Seed 5×10
6  PhoenixTM Amphotropic cells in 10 ml of growth medium containing serum 
(no antibiotics) in a 10 cm tissue culture plate so that they will be 90–95% confluent on 
the next day (day of transfection). 
 
2.  Day 2 
Before transfection, remove the culture medium from the PhoenixTM Amphotropic cells and 
replace with 5 ml of Opti-MEM® I Medium containing serum (no antibiotics). For each 
transfection sample (pLZRS-YFP-Parkin and pLZRS-empty vector (EV) expression plasmid 
DNA), prepare DNA-LipofectamineTM 2000 complexes as follows:  
2.1 In sterile 15 ml tubes, dilute 3 μg of each expression plasmid DNA 
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(pLZRS-EV and pLZRS-YFP-Parkin) in 1.5 ml of Opti-MEM® I Medium 
without serum and mix gently.  
 
2.2 In a separate sterile 15 ml tube, dilute 9 μl of LipofectamineTM 2000 in 
1.5 ml of Opti-MEM® I Medium without serum. Mix gently and incubate 
for 5 minutes at room temperature (20oC). Note: Mix LipofectamineTM 
2000 gently before use. 
 
2.3 After a 5-minute incubation, combine the diluted DNA with the diluted 
LipofectamineTM 2000 and mix gently.  Allow for DNA-
LipofectamineTM 2000 complexes formation by incubating for 20 
minutes at room temperature. The solution may appear cloudy, but this 
does not impede the transfection. 
2.4 Add the DNA-LipofectamineTM 2000 complexes dropwise to each plate 
of cells. Mix the plate gently by rocking back and forward and incubate 
cells overnight at 37°C in a humidified 5% CO2 incubator.  
Critical: Plasmid DNA for transfection into eukaryotic cells should very 
clean and free from contamination with phenol and sodium chloride. 
Contaminants can cause cytotoxicity, and salt will interfere with lipid 
complexing thereby decreasing transfection efficiency. 
3.  Day 3 
Remove  medium containing the DNA- LipofectamineTM 2000 complexes and replace 
with 10 ml complete culture medium (no antibiotics). Incubate at 37°C in a humidified 5% 
CO2 incubator. 
4.  Day 4 – 5 
 
4.1 Collect virus-containing supernatants 48 hours post-transfection into to a 15 
ml sterile, capped, conical tube. Collection of virus-containing supernatants can also 
be done 72 hours post-transfection, however minimal differences in viral yield are 
observed whether supernatants are collected at either 48 or 72 hours post-
transfection. 
Caution: At this stage, follow the guidelines for working with BL-2 organisms. 
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4.2 Centrifuge virus-containing supernatants at 1600 g for 15 minutes at 4°C to 
pellet debris, followed by supernatant filtration through a Millex-HV 0.45 μm or 
equivalent PVDF filter. This step prevents contamination of packaging cells (retroviral 
producers) into the cell line to be transduced.   
Caution: At this stage, follow the guidelines for working with BL-2 organisms. 
 
Steps 5 to 10 are a brief protocol of YFP-Parkin retroviral transduction in human primary 
fibroblasts. The procedure is similar for other mammalian cell lines. 
Timing: 15-17 days 
 
Critical: Transduction protocols are performed following BL-2 procedures. 
 
Critical: When using human primary cells, use cells at a lower PD in order to avoid 
producing a cell line that by the end of the transduction process is senescent or approaching 
senescence. To calculate the PD, cells should be trypsinized and counted for total number of 
cells calculation.  The following formula should then be applied: PD=X ± (Ln(n2/n1)/Ln2, 
where X is the number of the accumulated PD; n2 is the total number of cells obtained and 
n1 is the number of cells initially seeded in the plate. 
 
5. Day 1  
Seed 2 x 105 cells/well into a 6-well plate (cells should be 50-60% confluent at the time 
of transduction). Incubate cells at 37°C overnight in a humidified 5% CO2 incubator.  
Critical: Primary human fibroblasts do not form colonies when proliferating and 
therefore do not allow for viral titering, which permits optimization of viral transduction 
volumes for efficient transductions.  Furthermore, efficiency of transfection and viral 
particles generation can vary from experiment to experiment and with the size of the 
plasmid DNA. We advise performing transduction with several viral-supernatant 
volumes. Example: seed 3 wells in a 6-well plate: 1) for 1 mL viral transduction; 2) for 2 
mL viral transduction and 3) for non-transduced control (mock).  
 
6. Day 2  
Add the purified media with 10 μg/ml polybrene to cells at 50-60% cell confluency. 
Incubate at 37°C overnight in a humidified 5% CO2 incubator. Note that this step should 
be done immediately after step 4.2, thus seeding the cells for transduction (step 5) 
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should be performed the day before to viral collection. Alternatively, viral particles can 
be frozen at -80°C after collection and purification (note that in some cases transduction 
efficiency can be affected if using viral particles that were previously frozen; avoid 
freeze/thaw cycles). 
 
7. Day 3 
Remove the media containing viral particles and refresh the media with 2 ml of complete 
culture medium. Incubate at 37°C overnight in a humidified 5% CO2 incubator.  
Caution: Viral particle containing medium should be disposed according to BL-2 safety 
procedures. 
 
8. Day 4 
Remove the medium and wash the cells once with PBS. Trypsinize the cells and re-
plate all  cells (eachwell of a 6-well plate) into one 10 cm plate containing complete 
culture medium. Incubate at 37°C overnight in a humidified 5% CO2 incubator. 
Caution: Medium containing residual viral particles should be disposed according to BL-
2 safety procedures. 
 
9. Day 5 
For ZeocinTM selection, add 10 mL complete culture medium with 250 µM ZeocinTM to 
select for stably transduced cells. Human primary fibroblasts should be at 40-50% cell 
confluency when adding ZeocinTM for maximum selection efficiency. Replace medium 
with fresh medium containing 250 µM ZeocinTM every 3-4 days.  
Note: If using a different cell line, prior to this step a survival curve with different 
ZeocinTM concentrations should be performed on non-transduced cells to select for the 
lowest dose of ZeocinTM that causes 100% cell death. 
 
 
10. Day 15-17 
After 10-12 days of selection (day 14-16), stably YFP-Parkin expressing fibroblasts 
should have repopulated the transduced dish and no live cells should be observed in the 
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mock dish. Remove the medium and replace with complete media. During this period, 
efficiently transduced cells may need to be passaged into bigger flasks as they reach 
confluency. 
Critical: Store ZeocinTM at –20°C and thaw on ice before use. ZeocinTM is light 
sensitive. Store the drug, and medium containing drug, in the dark at 4°C. Culture 
medium containing ZeocinTM may be stored at 4°C protected from exposure to light for 
up to 1 month.  
 
Induction of widespread mitophagy 
Timing: 4 days, up to 6 days 
 
In this protocol, we describe general conditions for the induction of widespread mitophagy in 
primary cells. Despite following a similar protocol, primary and immortalised cells can differ 
in a few aspects of the protocol; below we describe the details regarding these differences. 
Critical: Cell density prior and during induction of widespread mitophagy can impact on the 
success of the protocol.  
 
11. Day 1 
11.1 Seed 1.5x 106 human primary fibroblasts (MRC5 or IMR90) (20<PD<25) into 10 
cm culture dishes in 10 ml of complete culture medium. Incubate cells at 37°C 
overnight in a humidified 5% CO2 incubator. 
11.2 Seed cells for mitochondria depletion QC assays: 5x105 cells/well in 6-well 
plates, for mitochondrial protein expression analysis by western blot or mtDNA 
copy number by qPCR, or 4x104 cells/well in coverslips in 12-well plates, for 
mitochondrial protein expression analysis by immunofluorescence staining, and 
incubate at 37°C overnight in a humidified 5% CO2 incubator. 
Note: Mitochondria depletion QC assays should be performed immediately after 
removal of the mitophagy inducer drug. Nevertheless, if the main experiment 
requires culturing cells for longer (e.g. 2 days after removal of the mitochondria 
uncoupler drug), then extra cells should be seeded and harvested, at the same 
time as the cells in the main experiment, for QC assays.  
Critical: Cells should be 70% confluent the next day. The number of cells seeded is 
dependent on the PD value, with advancing PDs cells start to become bigger (pre-
senescent), which impacts on cell culture density (e.g. lower PD cells require to be 
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seeded in higher density). It is, therefore, critical to adjust the number of cells to the PD 
value. 
Note: Other cell lines, particularly immortalised cells, may require different cell culture 
density when applying this protocol (e.g. HeLa cells should be at 10-20% confluency 
prior induction of mitophagy for optimal efficiency of the protocol). 
 
12. Day 2 – 3 
Treat cells every 24 hours, during 48 hours, with 12.5 µM CCCP in complete medium.  
Note:  Unlike primary cells, Immortalised cells (e.g. KP-4, HeLa, 3T3 and SVEC cells) 
are treated every 12 hours, during 48 hours, with 12.5 µM CCCP in complete medium. 
Cells can also be treated with 1 uM antimycin A and 1 uM oligomycin A in complete 
culture medium. If using other cell lines that are not mentioned in this protocol, the 
mitochondrial uncoupler dose and treatment duration may need to be adjusted.  
Critical: CCCP, antimycin A and oligomycin A are not stable in the media for longer 
periods of time and therefore need to be refreshed at least every 24 hours. 
 
 
13. Day 4 
Most cells lines tested have undergone extensive mitophagy at this point. At this stage, 
harvest cells for mitochondria depletion QC assays and proceed with the main 
experiment. 
 
13.1 Cells for mitochondrial depletion QC assays. Remove the medium containing 
CCCP and rinse cells once in pre-warmed PBS. Harvest cells for mitochondria 
depletion QC assays according to a pre-determined method (see below). 
13.2 Cells to proceed with the experiment. Remove the medium containing CCCP and 
rinse cells once in pre-warmed PBS. Refresh the medium with complete medium 
and incubate cells at 37°C in a humidified 5% CO2 incubator, for the duration of 
the experiment (up to 2 days post mitochondria depletion).  
Long-term culture of mitochondria-depleted cells 
Timing: 4 days, up to 30 days 
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Absence of mitochondria will impact on the function of the mitochondrial enzyme 
dihydroorotate dehydrogenase (DHODH) which is involved in pyrimidine synthesis (King and 
Attardi 1996). One way to overcome this is through the addition of uridine to the cell culture 
media. We have found that primary fibroblasts positively respond to the addition of uridine to 
the cell culture medium, allowing viability in culture for longer periods of time. Below, we 
describe how to culture mitochondria-depleted primary cells for a long period (up to 15 days 
in proliferating cells and up to 30 days in permanently arrested (senescent) cells). 
 
14. Day 1 
Seed 1.5x106 human primary fibroblasts (20<PD<25) into a 10 cm dish in complete 
media and allow cells to adhere at 37°C overnight in a humidified 5% CO2 incubator. 
Cells should be 70-90% confluent the next day. At the same time, seed cells for 
mitochondria depletion QC assays as described previously. 
 
Critical: It is critical that cells are 70 to 90% confluent prior treatment with the 
mitochondria uncoupler. Cell density will depend on the duration of the experiment: 
the longer the experiment the higher the cell density required prior treatment, as 
mitochondria-depleted cells tend to become smaller with time, compromising optimal 
cell density/contact and viability. 
 
15. Day 2 - 3 
Treat cells every 24 hours, over a 48 hour period, with 12.5 µM CCCP in complete 
medium. Cells can also be treated with 1 uM antimycin A and 1 uM oligomycin A in 
complete culture medium.  
Critical: CCCP, antimycin A and oligomycin A are not stable in the media on cells for 
longer periods of time and therefore need to be refreshed at least every 24 hours. 
Different primary cells may need adjusting drug refreshment periods. 
 
16. Day 4 
Remove medium containing CCCP and replace with complete medium with 
additional 50ug/ml uridine. Incubate cells at 37°C in a humidified 5% CO2 incubator. 
At this point cells should de devoid of mitochondria, collect cells for mitochondria 
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depletion QC assays, as described previously. 
17. Day 5-up to 15 
Refresh medium supplemented with 50ug/ml uridine every 2 days until the end of 
your experiment. By the end of the experiment harvest cells for the main experiments 
and cells for mitochondria depletion QC assays as described previously. 
 
Critical: In long-term experiments, it is critical for cell fitness and viability that cells 
are cultured in medium supplemented with uridine, as it will partially overcome the 
limiting pyrimidine levels in mitochondria-depleted cells. Secondly, mitochondrial 
depletion should also be assessed at long-term post-depletion, to ensure viable cells 
are not simply the ones that escaped initial depletion.  
 
 
Readouts of widespread mitophagy 
We suggest the following conventional methods for determination of widespread 
mitochondria: western blotting (see Figure 2A & G), immunofluorescence staining for specific 
mitochondrial proteins followed by microscopy and/or flow cytometry analysis (see Figure 2D 
& E) and qPCR for mtDNA copy number (see Figure 2E). Antibodies used for Western 
blotting and Immmunofluorescence and primers for mtDNA copy number assays are 
described in the Material section. 
Furthermore, we can detect clearance of mitochondria by live cell imaging of YFP-Parkin 
cells expressing a mitochondrial targeted protein (for instance mito-dsRRed) (See video 
Figure 1). Briefly, for live-cell imaging, plate YFP-Parkin expressing cells, transiently 
expressing mitochondrial targeted dsReD (mito-dsRed), on 35 mm glass-bottom dishes and 
image using a long-term time lapse Nikon TE2000 microscope. Prior to imaging, treat cells 
with antimycin and oligomycin using the protocol described above. 
  
Troubleshooting 
Troubleshooting advice can be found in Table 4. 
 
Timing 
Generation of Parkin encoding retrovirus, 4 – 5 days. Retroviral transduction and selection of 
Parkin expressing cells, 15 – 17 days. Induction of widespread mitophagy, 4 – 5 days. Long 
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term culture of mitochondria-depleted cells, up to 30 days. QC analysis of mitochondrial 
depletion, 2 – 3 days. 
 
Anticipated results 
In Figure 2, we show different experiments that validate the complete removal of 
mitochondria using the widespread mitophagy protocol. In panel A, KP-4 YFP-Parkin cells 
were treated with A/O for 48 hours and then immunoblotted with Mitoprofile. In panels B and 
C the same cells were immunostained for COXIV and TIMM44 and no mitochondria were 
observed. In panel D, we confirm mitochondrial depletion by using FACS for the same 
proteins as in B and C. In panel F we illustrate the procedure for clearance of mitochondria 
followed by long-term culture of cells (only applicable to human primary fibroblasts). In panel 
G we show expected western blotting results for several mitochondrial proteins: NDUFB8, 
SDHA, UQCRC2 and TOMM20 at day 4 and 16 after removal of CCCP. These results 
demonstrate that the initial CCCP treatment is sufficient for clearance of mitochondria and 
no repopulation occurs at later stages. 
 
 
Figure legends 
Figure 1. Overview of enforced mitophagy protocol 
Cells stably expressing YFP-Parkin are treated with CCCP or a combination of Antimycin A 
and Oligomycin A for up to 48 h. This disrupts the mitochondrial inner membrane potential 
(∆ψm), leading to PINK1 accumulation on the outer mitochondrial membrane and Parkin 
activation and recruitment at the mitochondria. Here, Parkin ubiquitinates a multitude of 
mitochondrial proteins that serves as signal for autophagosome engulfment of damaged 
mitochondria. Ultimately, all mitochondria are removed via mitophagy. 
 
Figure 2. Validating Parkin-mediated widespread mitophagy  
A. KP-4 cells stably expressing YFP-Parkin were treated with antimycin A and oligomycin A 
(AO) for 48 hours and then immune-blotted with a cocktail of antibodies recognizing various 
mitochondrial proteins. B-C. Following induction of mitophagy, KP-4 YFP-Parkin cells were 
immuno-stained for the mitochondrial proteins COXIV (B) and TIMM44 (C). Scale bar is 50 
μm. D. Flow cytometry analysis showing reduced levels of COXIV and TIMM44 in AO-treated 
KP-4 cells expressing YFP-Parkin. E. mtDNA quantitative PCR on KP-4 YFP-Parkin cells after 
induction of mitophagy. A representative experiment (out of two) is shown with error bars 
representing standard deviation for three technical replicates. F. Workflow of widespread 
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mitophagy and long-term culture of human primary fibroblast with depleted mitochondria. 
G. Western blot analysis for mitochondrial content in primary fibroblasts 4 and 16 days after 
CCCP release.     
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Table 1 | Cell lines for the generation of a stable YFP-Parkin-expressing cell line 
Cell line Species Source Cell type Application 
Phoenix 
Amphotropic 
Human ATCC (Cat. 
Number CRL-
3213) 
Immortalised Viral particles 
generation 
 
 
MRC5 
Fibroblasts 
Human ECACC, Salisbury, 
UK (Cat. Number 
05011802) 
Primary Viral transduction and 
generation of a stable 
YFP-PARKIN-
expressing cell line 
 
IMR-90 
Fibroblasts 
 
Human ECACC, Salisbury, 
UK (Cat. Number 
85020204) 
Primary Viral transduction and 
generation of a stable 
YFP-PARKIN-
expressing cell line 
 
KP-4 
 
Human RIKEN Immortalised Viral transduction and 
generation of a stable 
YFP-PARKIN-
expressing cell line 
 
U2OS Human ATCC (Cat. 
Number HTB-96) 
Immortalised Viral transduction and 
generation of a stable 
YFP-PARKIN-
expressing cell line 
 
MCF-7 Human ATCC (Cat. 
Number HTB-22) 
Immortalised Viral transduction and 
generation of a stable 
YFP-PARKIN-
expressing cell line 
 
HeLa   Human ATCC (Cat. 
Number CCL-2) 
Immortalised Viral transduction and 
generation of a stable 
YFP-PARKIN-
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expressing cell line 
 
3T3-SA Mouse ATCC (Cat. 
Number CCL-92) 
Immortalised Viral transduction and 
generation of a stable 
YFP-PARKIN-
expressing cell line 
 
NIH-3T3 
 
Mouse ATCC (Cat. 
Number CRL-
1658) 
Immortalised Viral transduction and 
generation of a stable 
YFP-PARKIN-
expressing cell line 
 
SVEC Mouse ATCC (Cat. 
Number CRL-
2167) 
Immortalised Viral transduction and 
generation of a stable 
YFP-PARKIN-
expressing cell line 
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Table 2 | Antibodies for widespread mitophagy QC assays 
Primary Antibodies
 
Antibody 
 
Species 
 
Host 
 
Reference/ 
Manufacturer 
 
WB 
(dilution) 
 
IMF 
(dilution) 
 
MitoProfile 
Membrane 
Integrity 
antibody 
cocktail 
 
Human 
Mouse 
Rat 
Cow 
 
Mouse 
monoclonal 
ab110414/ 
Abcam 
1:1000 _________ 
 
TIMM44 
 
Human 
Mouse 
 
 
Rabbit 
monoclonal 
 
ab194829/ 
Abcam 
 
-------------
- 
 
1:200 
COXIV Human 
Mouse 
Rat 
Monkey 
Mouse 
monoclonal 
11967/ 
Cell Signaling 
-------------
- 
1:200
 
SDHA 
 
Human 
Mouse 
 
Rabbit 
monoclonal 
 
#11998/ 
Cell Signaling 
 
1:1000 
 
1:100 
 
NDUFB8 
 
Human 
Mouse 
 
Mouse 
monoclonal 
 
ab110242 - 
Abcam 
 
1:1000 
 
_________ 
 
UQCRC2 
 
Human 
Mouse 
 
Mouse 
monoclonal 
 
ab14745  -  
Abcam 
 
1:1000 
 
_________ 
 
TOMM20 
 
Human 
Mice 
 
Mouse 
monoclonal 
ab56783 -   
Abcam 
1:1000 _________ 
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GAPDH 
 
Human 
Mouse 
 
Rabbit 
monoclonal 
 
#5174/ 
Cell sigalling 
 
1:5000 
 
_________ 
 
α-tubulin 
 
 
Human 
Mouse 
rat 
 
Mouse 
monoclonal 
 
T6074/ 
Sigma-Aldrich 
 
1:5000 
 
_________ 
 
actin 
 
 
Mammals 
Yeast 
Fungi 
 
Mouse 
monoclonal 
 
8691001/ 
MP 
Biomedicals 
 
1:5000 
 
_________ 
Secondary Antibodies
Secondary antibody 
 
Reference/ 
Manufacturer 
 
WB 
(dilution) 
 
IMF 
(dilution) 
 
Anti-rabbit Fluorescein-
conjugated secondary 
antibody AlexaFluor 647 
 
A21244/ 
Molecular Probes 
________ 1:1000 
 
Goat anti-rabbit IgG -HRP 
conjugated 
 
A0545/ 
Sigma-Aldrich 
1:5000 _________ 
Rabbit anti-mouse IgG -HRP 
conjugated 
 
A2554/ 
Sigma-Aldrich 
 
1:5000 _________ 
Table 3 | Primers for mtDNA qPRC 
 28
 
 
 
 
Gene  Primer Forward Primer Reverse
mtDNA MTRNR2 CGAAAGGACAAGAGAAATAAGG 
mtDNA MTTL1  CTGTAAAGTTTTAAGTTTTATGCG
nuclear β-Globin CAACTTCATCCACGTTCACC GAAGAGCCAAGGACAGGTAC 
 Table 4 | Troubleshooting
Step Problem Possible reason Possible solution 
 
1-10 
 
None or few 
cells expressing 
YFP-Parkin 
 
Inefficient viral transfection 
that can be a result of:  
 
a) Loss of viral packaging 
plasmid in the PhoenixTM 
Amphotropic cells during 
replication. 
 
 
b) Suboptimal cell density. If 
cell density at the time of 
transfection is suboptimal 
(low cell density) cells may 
not be in the optimal growth 
phase for transfection. This 
can result in insufficient 
uptake of plasmid DNA-
Lipofectamin complexes into 
the cells. 
 
 
 
 
It is important that cells are 
previously selected with the 
respective selecting 
antibiotics (Hygromycin B and 
Diphteria toxin). 
 
PhoenixTM Amphotropic cells 
should be 90-95% confluent 
by the time of transfection. 
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Inefficient viral transduction 
that can be a result of:  
 
a) Low viral particles being 
generated by the packaging 
cells.  
 
 
 
 
 
b) Suboptimal concentration 
of polybrene during the 
transduction process. 
 
 
 
 
 
 
  
 
 
 
c) Excessive antibiotic used 
for selection. 
 
 
 
 
See above for possible 
solutions. 
 
 
 
 
 
 
Determine the concentration 
of polybrene to be used in 
the cell line of interest with 
minor toxic effects. For MRC5 
fibroblast, 10µg/ml is the 
optimal concentration of 
polybrene for an efficient 
transduction. Note that some 
cell lines are particularly 
sensitive to polybrene, in this 
case do not use polybrene. 
 
 
Determine the antibiotic 
sensitivity of the cell line of 
interest by performing a 
survival curve. Use the 
minimum antibiotic required 
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to kill non-transduced cells. 
For the cell lines described in 
this protocol, 250 µM of 
ZeocinTM is the optimal 
antibiotic concentration. 
 
12 Incomplete 
mitophagy 
Loss of CCCP efficiency
 
 
 
 
 
 
Suboptimal mitochondrial 
membrane uncoupling 
treatment  
 
 
 
 
Suboptimal cell density. Cell 
density, prior and during 
mitochondria membrane 
uncoupling, is a major 
determinant of cell viability 
upon complete mitophagy. 
Low cell confluency, prior 
and during uncoupling, may 
result in cell death. 
 
 
CCCP is photosensitive. It is 
critical to aliquot very small 
volumes (e.g. 10 µl) of CCCP, 
store it at -20oC and protect it 
from light in order to 
maintain its efficiency. 
 
Perform a drug concentration 
and treatment duration 
(including drug refreshment 
periodicity) testing, if using a 
different cell line to the ones 
described in this protocol. 
 
Primary fibroblasts require 
70-90% cell density, prior and 
during treatment, for optimal 
cell viability post treatment. 
However, other cells lines, 
particularly immortalized 
lines (e.g. HeLa cells) require 
lower cell confluency using 
this protocol. Determine the 
optimal cell density for the 
cell line of interest is crucial 
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for the success of the 
protocol. 
Optional: A possibility to 
avoid cell death is the 
treatment with caspase 
inhibitors. 
 
12 High rate of cell 
death during 
mitochondria 
uncoupling 
Suboptimal mitochondrial 
membrane uncoupling 
treatment. CCCP can be toxic 
to cells if used in 
inappropriate doses and 
treatment duration and 
periodicity. 
For the cell lines described in 
this protocol, 12.5 µM of 
CCCP is the optimal dose 
promoting complete 
mitophagy, with minimal cell 
toxicity or off target effects. 
However, if using different 
cell lines to the ones 
described in this protocol, 
perform a CCCP 
concentration dependent 
survival curve and determine 
the optimal drug dose and 
treatment duration and 
periodicty. 
 
13 High rate of cell 
death shortly 
post complete 
mitophagy 
 
Suboptimal cell density. See above (step 12) 
17 Premature loss 
of cell viability 
in long-term 
Suboptimal cell density  
 
 
For primary fibroblasts, cells 
should be 70% confluent 
prior mitochondria 
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experiments  
 
 
 
 
 
Suboptimal concentration of 
uridine.  In long-term 
experiments, it is critical for 
cell fitness and viability that 
cells are cultured in medium 
supplemented with uridine 
to overcome the limiting 
pyrimidine levels in 
mitochondria-depleted cells. 
membrane uncoupling 
treatment and 90% confluent 
after re-seeding cells for 
experiments post-induction 
of complete mitophagy. 
 
For primary fibroblasts, 
supplement the cell culture 
medium with 50 mg/ml of 
uridine. Other cells lines may 
have different uridine 
requirements, therefore 
determining the uridine 
concentration for the cell line 
of interest is fundamental for 
extension on cell viability in 
mitochondria-depleted cell. 
    


